| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider activity in RDHL over the last quarter tilts toward selling: insiders offloaded a net 14,310,000 shares worth roughly $1K. In the past 30 days, 0 insiders bought and 1 sold.
On the other side, 1 insider reduced a position over the period. RDHL sits in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector, so this activity is best read against the sector's broader insider trend.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| COO | 176.91M | $17.7K | -14,310,000 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Raday Gilead | Chief Operating Officer | Sale+OE | 14,310,000 | $0.00 | $1,431.00 | -7.5% | |
| Jul 10, 2026 | Raday Gilead | Chief Operating Officer | Sale+OE | 14,130,000 | $0.00 | $1,413.00 | -6.1% | |
| Apr 6, 2026 | Raday Gilead | Chief Operating Officer | Sale+OE | 15,740,000 | $0.00 | $1,574.00 | -5.7% |